“…Rheumatoid arthritis-FLSs treated with full-length IL-38 promoted the activation of ERK, JNK, and P38, and accelerated RA-FLSs migration and invasion. 99 In contrast, RA-FLSs treated with IL-1β showed less expression of IL-6 and IL-8, inhibited activation of ERK, JNK, and P38, and suppressed RA-FLSs migration and invasion. Addition of full-length IL-38 suppressed IL-1β-induced effects on RA-FLSs, suggesting that full-length IL-38 may act as a promoter in RA by regulating IL-1β.…”